Phenotyping and Characterization of wtATTR-CM (TRACE 1)
Recruiting
Observational Study
Transthyretin Amyloidosis
Transthyretin Amyloid Cardiomyopathy
Wild-Type Transthyretin-Related (ATTR)Amyloidosis
Quality of Life
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 120 (estimated)
- Sponsor
- Steen Hvitfeldt Poulsen · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Descriptive cross-sectional study on 100 consecutive ATTRwt-CM patients reflecting all NAC stages aiming primarily to investigate ATTRwt-CM patient's quality of life (QoL) measures and their relation to ATTRwt-CM severity. Secondarily aiming to investigate the possibility to measure misTTR and fragTTR in plasma and urine and to detect fragTTR in endomyocardial biopsies from ATTRwt-CM patients. To …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Group 1: wtATTR-CM patients
Inclusion Criteria:
* Patients \> 18 years diagnosed with ATTRwt-CM by:
* endomyocardial biopsy
* DPD scintigraphy with Perugini grade 2-3 where variant amyloidosis is ruled out due to genetic testing.
* Informed oral and written consent
Exclusion Criteria:
* AL amylo…
Contacts